---
title: CNS Infection
fileClass: share
creation date: 2024-08-09 16:05
tags:
  - teaching
  - medicine/CNS
status: finished
share_link: https://share.note.sx/1uhhve6q#nCOpir4CQ8PllcQCjkfpY6sYlK4FQVHe1lC2ON4rTeQ
share_updated: 2024-08-14T16:04:25+08:00
share: true
category: medicine
alias: cns-infection
---
# CNS Infection  
source:: Pocket Medicine, 2022  
## 急性細菌性腦膜炎  
  
### 定義  
  
- 腦/脊髓周圍組織的發炎  
- 通常起源於鼻咽部（血行播散）、菌血症或直接接種（手術、鄰近感染、創傷、異物［如腦脊液分流管］）  
#### **細菌性腦膜炎中的微生物學** (_NEJM_ 2011;364:2016)  
  
| 病原體                                 |                                                                                                            |  
| ----------------------------------- | ---------------------------------------------------------------------------------------------------------- |  
| _Streptococcus pneumoniae_ (30-60%) | 常見於有前驅感染（菌血症、肺炎、心內膜炎）患者<br><br>抗藥性_S. pneumoniae_:<br> - 約40%對PCN抗藥（即使是中度抗藥也很麻煩）<br>- 約10%對第三代頭孢菌素抗藥       |  
| _Neisseria meningitidis_ (10-35%)   | 主要見於年齡小於30歲的患者，常伴有瘀點或紫斑<br><br>在無脾症、補體缺乏、HIV、SCT、未接種疫苗者中風險增加<br><br>建議所有11-18歲的青少年、HIV感染者、無脾症者、C5-9缺乏者接種疫苗 |  
| _Haemophilus influenzae_ (<5%)      | 無脾症、補體缺乏、HIV、SCT、未接種疫苗、腦脊液漏、創傷/手術、乳突炎患者中風險增加<br><br>建議所有兒童接種疫苗；發病率顯著降低                                     |  
| _Listeria monocytogenes_ (5-10%)    | 在免疫抑制（類固醇使用、移植）、老年人、惡性腫瘤、孕婦、肝硬化患者中增加<br>爆發常與受污染的乳製品和生蔬菜有關                                                  |  
| GNBs (1-10%)                        | 在與醫療保健相關的腦膜炎中較常見（如_Escherichia coli_、_Klebsiella_、_Pseudomonas aeruginosa_）                                |  
| _Staphylococci_ (5%)                | 前驅感染（心內膜炎、菌血症）、CNS手術後、異物（腦脊液分流管、硬膜下幫浦）相關                                                                   |  
| 混合感染                                | 應懷疑顱旁感染灶或腦脊液漏、CNS手術後感染                                                                                     |  
  
### 臨床表現 (Lancet 2016;339:16)  
  
- 頭痛 (84%)、發燒 (74%)、頸部僵硬 (74%)、畏光、GCS <14 (71%)、噁心 (62%)、癲癇發作 (23%)；95%患者有以下4種症狀中的2種：頭痛、發燒、頸部僵硬、意識改變  
- 老年人和免疫抑制患者的表現可能不典型（如沒有發燒的嗜睡）  
  
### 體檢 (CID 2002;35:46; Am J Emerg Med 2013;31:1601)  
  
- 頸部僵硬（靈敏度 30%，特異性 68%）、Kernig’s sign（靈敏度 5%，特異性 95%）、Brudzinsk’s sign（靈敏度 5%，特異性 95%）、Jolt’s sign（頭痛隨水平轉動惡化）（靈敏度 64%，特異性 43%）  
- ± 局部神經病學發現（約30%；偏癱、失語症、視野缺損、顱神經麻痺）  
- ± 頭頸耳鼻喉發現：鼻竇壓痛、清澈鼻漏（腦脊液漏）  
- ± 皮膚和關節發現：瘀點疹（_N. meningitidis_）、生殖器或口腔潰瘍（HSV）、伴隨關節積液的關節炎（_N. meningitidis_）  
  
### 細菌性腦膜炎的順序管理  
  
- 血液培養，開始經驗性抗生素，考慮使用類固醇（見下文）  
- 如有適應症，進行頭部CT檢查（見下文）  
- 儘快進行腰椎穿刺（如果沒有禁忌症）；如果在開始抗生素後約4小時內獲得腦脊液培養，結果不太可能會改變  
  
### 診斷研究 (NEJM 2017;388:3036)  
  
- 在使用抗生素前進行2次血液培養  
- 在健康宿主的細菌性腦膜炎中，白血球計數 >10,000 的機率超過90%  
- 如果有1個以上的高風險因素，如免疫抑制、CNS疾病史、新發癲癇發作、局部神經學發現、乳頭水腫、GCS <15，則需在腰椎穿刺前進行頭部CT以排除腫瘤效應 (CID 2004;39:1267)  
- 腰椎穿刺並測量前壓 (NEJM 2006;355:e12)  
- 將腦脊液送檢進行細胞計數和分類、葡萄糖、蛋白質、革蘭氏染色、細菌培養  
- 根據臨床懷疑進行額外的腦脊液研究：抗酸桿菌染色/培養（或MTb PCR）、隱球菌抗原、真菌培養、VDRL、PCR（HSV、VZV、腸道病毒）、細胞學  
- 腦脊液革蘭氏染色的靈敏度為30-90%；如果腰椎穿刺在使用抗生素前進行，培養的靈敏度為80-90%，但如果懷疑為細菌性腦膜炎，抗生素應不延遲使用  
- 2的規則：**腦脊液白血球>2000、葡萄糖<20、蛋白質>200**，對細菌性腦膜炎的特異性超過98%  
- 如適當抗生素治療48小時後無臨床反應或腦脊液分流，則需重複腰椎穿刺  
- 次世代定序技術可提高診斷率 (NEJM 2019;380:2327)  
  
#### 腦膜炎中典型的腦脊液發現  
  
| **類型**        | **外觀**    | **壓力（cm H2O）** | **WBC/mm³ *主導類型*** | **Glc（mg/dL）** | **TP (mg/dL)** |  
| ------------- | ----------- | ------------------- | --------------------- | --------------- | -------------- |  
| **正常**      | 清澈        | 9-18                | 0-5 _淋巴細胞_        | 50-75           | 15-40          |  
| **細菌性**    | 渾濁        | 18-30               | 100-10,000 _多形核細胞_ | <45             | 100-1000       |  
| **結核性**    | 渾濁        | 18-30               | <500 _淋巴細胞_       | <45             | 100-200        |  
| **真菌性**    | 渾濁        | 18-30               | <300 _淋巴細胞_       | <45             | 40-300         |  
| **無菌性**    | 清澈        | 9-18                | <300 _多形核細胞_ → _淋巴細胞_ | 50-100          | 50-100         |  
  
### 細菌性腦膜炎的經驗性治療 (_Lancet_ 2012;380:1693)  
  
| **50歲以下成人**            | Ceftriaxone + vancomycin（濃度15-20），考慮靜脈注射acyclovir                                                  |  
| ---------------------- | -------------------------------------------------------------------------------------------------- |  
| **50歲以上成人**            | Ceftriaxone + vancomycin + ampicillin，考慮靜脈注射acyclovir                                              |  
| **免疫抑制者**              | [Cefepime或meropenem] + vancomycin ± ampicillin（如果已使用meropenem，則不需要ampicillin），考慮靜脈注射acyclovir和真菌覆蓋 |  
| **醫療相關感染（如手術、腦脊液分流管）** | [Cefepime或meropenem或ceftazidime] + vancomycin                                                      |  
  
- 可能的話，應根據敏感性或當地的抗藥模式使用針對病原體的治療  
- 確認適當的劑量，因為腦膜炎中通常需要更高的劑量（但可能需要根據腎功能進行調整）  
- **類固醇**：如果病原體未知，建議在開始抗生素前或與其同時使用dexamethasone靜脈注射10毫克，每6小時一次，連續4天。對於***S. pneumoniae*和GCS 8-11**的患者有最大的益處（神經殘疾和死亡率降低約50%）。==避免使用於隱球菌感染==（NEJM 2016;374:542）。  
- 預防性措施：對於*N. meningitidis*的密切接觸者，使用rifampin（600 mg口服，每日兩次，持續2天）或ciprofloxacin（500 mg口服，一次）或ceftriaxone（250 mg肌肉注射，一次）  
- 預防措施：在排除*N. meningitidis*之前，採取飛沫隔離措施  
  
## 無菌性腦膜炎  
  
### 定義  
  
- 臨床/實驗室證據顯示腦膜發炎，但細菌培養（腦脊液及血液）結果為陰性  
  
### 病因學 (Neurology 2006;66:75)  
  
- 病毒性：腸病毒是最常見的原因（夏季/秋季；皮疹、腸胃道症狀、上呼吸道感染症狀），HIV、HSV、VZV、腮腺炎、淋巴細胞性脈絡腦膜炎病毒（與齧齒動物接觸）、腦炎病毒、腺病毒、小兒麻痹病毒、CMV、EBV、西尼羅河病毒  
- 局部細菌感染：腦/硬膜外/硬膜下膿瘍，中樞神經系統敗血性血栓靜脈炎  
- 治療過的細菌性腦膜炎  
- 其他感染：結核、真菌（隱球菌、球黴菌）、萊姆病、梅毒、鈎端螺旋體病  
- 腫瘤：顱內腫瘤（或囊腫）、淋巴瘤性或癌性腦膜炎  
- 藥物引起的腦膜炎：NSAIDs、靜脈注射免疫球蛋白、抗生素（TMP-SMX、penicillin）、抗癲癇藥  
- 系統性自體免疫疾病：SLE、類肉瘤、貝賽特氏病、乾燥綜合症、類風濕性關節炎  
- Mollaret's：反覆性淋巴細胞性腦膜炎，會自己緩解（通常為HSV-2）  
  
### 診斷  
  
- 進行腰椎穿刺以進行腦脊液分析：病毒性病因中常見淋巴細胞增多症（見上方腦膜炎中的典型腦脊液發現表格）  
- 考慮腦脊液細胞學和腦部/脊髓MRI以評估是否有惡性腫瘤  
- 如果腦脊液檢查無所發現且經驗性治療無改善，在適當情況下考慮進行血清自體免疫及病毒檢測  
  
### 經驗性治療  
  
- 懷疑為細菌性腦膜炎：參見上方細菌性腦膜炎的經驗性治療  
- 懷疑為病毒性腦膜炎：如果懷疑為HSV腦膜腦炎 → 靜脈注射acyclovir  
- 病因不明：考慮開始經驗性細菌性腦膜炎治療，同時觀察並等待腦脊液檢查結果  
  
## 腦炎 (NEJM 2018;379:557)  
  
### 定義  
  
- 腦實質發炎，特徵為腦功能受損（意識改變、神經缺損），通常由原發性病毒感染或病毒感染後發炎引起  
  
### 病因學 (特定病因在<20%的病例中找到; Neurology 2006;66:75; CID 2008;47:303)  
  
- **HSV-1**：所有年齡/季節。如果治療後症狀復發，考慮為病毒復發或自體免疫性腦炎，因為數週後自體免疫疾病的發病率很高 (Lancet Neurol 2018;17:760)  
- VZV原發性感染或再活化：± 水泡疹；所有年齡（偏向老年人），所有季節  
- 蟲媒病毒：評估病媒蚊/地理暴露。蚊子：日本腦炎、西尼羅河病毒。  
- 腸病毒（coxsackie, echo）：上呼吸道感染/腸胃道症狀前驅；夏末/秋初達高峰  
- 其他感染：CMV、EBV、HIV、JC病毒、麻疹、腮腺炎、狂犬病、腺病毒、流感病毒、萊姆病  
- 非感染性：自體免疫/副腫瘤（抗NMDAR、抗Hu、抗Ma2、抗CRMP5、抗mGluR5），感染後脫髓鞘（例如，ADEM）  
  
### 臨床表現  
  
- 發燒 + 意識狀態改變（輕微至嚴重）、癲癇發作、局部神經缺損、腦膜腦炎中的頭痛  
  
### 診斷研究 (CID 2013;57:1114)  
  
- 腦脊液分析：淋巴細胞增多症；HSV（95% 敏感度和特異度）、VZV的PCR；根據風險因素考慮其他PCR檢查（CMV/EBV、HIV、JC病毒、腺病毒/腸病毒、西尼羅河病毒）  
- 如果腦脊液檢查無所發現且經驗性HSV/VZV治療無改善，在適當情況下考慮檢測自體免疫病因及血清病毒檢測  
- MRI（如果無法進行則使用CT）；HSV：顳葉；西尼羅河病毒和Powassan病毒：丘腦高信號  
- EEG排除癲癇；腦炎中的發現非特異性（HSV的顳葉重點）  
  
### 治療  
  
- HSV/VZV：Acyclovir 10 mg/kg 靜脈注射，每8小時一次；考慮經驗性治療，因為機率較高  
  
## ACUTE BACTERIAL MENINGITIS  
  
### Definition  
  
- Inflammation of tissue around the brain/spinal cord  
- Usually arising from nasopharynx (hematogenous spread), bacteremia, or direct inoculation (surgery, contiguous infection, trauma, foreign body [eg, CSF shunt])  
  
#### **Microbiology in Bacterial Meningitis** (_NEJM_ 2011;364:2016)  
  
| Pathogen                   |                                                                                                                                                                                                                            |  
| -------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |  
| _S. pneumoniae_ (30-60%)   | Look for preceding infection (bacteremia, pneumonia, endocarditis)<br><br>Drug-resistant _S. pneumoniae:_<br>  ˜40% PCN-resistant (even _intermediate_ resistance problematic)<br>  ˜<10% 3rd-gen. cephalosporin-resistant |  
| _N. meningitidis_ (10-35%) | Primarily in age <30 y; associated petechiae or purpura<br><br>↑ risk in asplenia, complement defic., HIV, SCT, unvaccinated<br><br>Vaccine rec for all age 11-18 y, HIV infection, asplenia, C5-9 deficiency              |  
| _H. influenzae_ (<5%)      | ↑ risk in asplenia, complement defic., HIV, SCT, unvaccinated, CSF leak, trauma/surgery, mastoiditis<br><br>Vaccine rec for all children; markedly ↓ incidence                                                             |  
| _L. monocytogenes_ (5-10%) | ↑ in immunosupp (glucocorticoids, transplant), elderly, malignancy, pregnant, cirrhosis. Outbreaks a/w contaminated dairy & raw veg.                                                                                       |  
| GNBs (1-10%)               | More common in health care associated meningitis (_E. coli, Klebsiella sp., Pseudomonas aeruginosa)_                                                                                                                       |  
| _Staphylococci_ (5%)       | Preceding infection (endocarditis, bacteremia), post CNS surgery, foreign bodies (CSF) shunt, intrathecal pump)                                                                                                            |  
| Mixed infection            | Suspect parameningeal focus or CSF leak, post CNS surgery                                                                                                                                                                  |  
### Clinical manifestations (Lancet 2016;339:16)  
- Headache (84%), fever (74%), stiff neck (74%), photosensitivity, GCS <14 (71%), nausea (62%), seizure (23%); 95% have 2 of 4: HA, fever, stiff neck, ΔMS  
- Presentation may be atypical (eg, lethargy w/o fever) in elderly and immunosupp.  
  
### Physical exam (CID 2002;35:46; Am J Emerg Med 2013;31:1601)  
- Nuchal rigidity (Se 30%, Sp 68%), Kernig's sign (Se 5%, Sp 95%), Brudzinski's sign (Se 5%, Sp 95%), jolt sign (HA worsens w/ horizontal rotation) (Se 64%, Sp 43%)  
- ± Focal neuro findings (˜30%; hemiparesis, aphasia, visual field cuts, CN palsies)  
- ± HEENT findings: sinus tenderness, clear rhinorrhea (CSF leak)  
- ± Skin and joint findings: petechial rash (N. meningitidis), genital or oral ulcers (HSV), arthritis with joint effusion (N. meningitidis)  
  
### Sequential management of bacterial meningitis  
- Blood cx, initiate empiric antibiotics, consider corticosteroids (vide infra)  
- CT head if indicated (see below)  
- LP ASAP (if not contraindicated); yield of CSF cx unlikely to be changed if obtained w/in ˜4 h of initiation of abx  
  
### Diagnostic studies (NEJM 2017;388:3036)  
- Blood cultures ×2 before abx  
- WBC count: >10,000 in >90% of bacterial meningitis in healthy hosts  
- Head CT to r/o mass effect before LP if ≥1 high-risk feature: immunosupp., h/o CNS disease, new-onset seizure, focal neuro findings, papilledema, GCS <15 (CID 2004;39:1267)  
- Lumbar puncture with opening pressure (NEJM 2006;355:e12)  
- Send CSF for cell count and differential, glucose, protein, Gram stain, bacterial cx  
- Additional CSF studies based on clinical suspicion: AFB smear/cx (or MTb PCR), cryptococcal Ag, fungal cx, VDRL, PCR (HSV, VZV, enteroviral), cytology  
- CSF Gram stain has 30-90% Se; cx 80-90% Se if LP done prior to abx though abx should not be delayed for LP if there is concern for bacterial meningitis  
- Rule of 2s: **CSF WBC >2k, gluc <20, TP >200** has >98% Sp for bacterial meningitis  
- Repeat LP only if no clinical response after 48 h of appropriate abx or CSF shunt  
- Metagenomic next-generation sequencing ↑ dx yield (NEJM 2019;380:2327)  
  
#### Typical CSF Findings in Meningitis  
  
| **Type**      | **Appearance** | **Pressure (cm H2O)** | **WBC/mm3 *Predom Type*** | **Glc (mg/dL)** | **TP (mg/dL)** |  
| ------------- | -------------- | --------------------- | ------------------------- | --------------- | -------------- |  
| **Normal**    | Clear          | 9-18                  | 0-5 _lymphs_              | 50-75           | 15-40          |  
| **Bacterial** | Cloudy         | 18-30                 | 100-10,000 _polys_        | <45             | 100-1000       |  
| **TB**        | Cloudy         | 18-30                 | <500 _lymphs_             | <45             | 100-200        |  
| **Fungal**    | Cloudy         | 18-30                 | <300 _lymphs_             | <45             | 40-300         |  
| **Aseptic**   | Clear          | 9-18                  | <300 _polys_ → _lymphs_   | 50-100          | 50-100         |  
### Empiric Treatment of Bacterial Meningitis (_Lancet_ 2012;380:1693)  
  
| **Adults <50 y**                                         | Ceftriaxone + vancomycin (trough 15-20), consider acyclovir IV                                             |  
| -------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------- |  
| **Adults >50 y**                                         | Ceftriaxone + vancomycin + ampicillin, consider acyclovir IV                                               |  
| **Immunosuppressed**                                     | [Cefepime _or_ meropenem] + vanc ± amp (not nec. if on meropenem), consider acyclovir IV & fungal coverage |  
| **Healthcare assoc. infection (eg, surgery, CSF shunt)** | [Cefepime _or_ meropenem _or_ ceftazidime] + vancomycin                                                    |  
- When possible, organism-directed Rx, guided by sensitivities or local patterns of drug resistance should be used  
- Confirm appropriate dosing as higher doses are often needed in meningitis (though may need to be adjusted for renal function)  
- **Corticosteroids**: If causative organism is unknown, dexamethasone 10 mg IV q6h × 4 d recommended prior to or with initiation of abx. Greatest benefit in ***S. pneumoniae* and GCS 8-11** (↓ neuro disability & mortality by ˜50%). ==Avoid in crypto== (NEJM 2016;374:542).  
- Prophylaxis: for close contacts of Ptw/N. meningitidis; rifampin (600 mg PO bid × 2 d) or ciprofloxacin (500 mg PO × 1) or ceftriaxone (250 mg IM × 1).  
- Precautions: droplet precautions until N. meningitidis is ruled out  
  
## ASEPTIC MENINGITIS  
  
### Definition  
  
- Clinical/lab evidence of meningeal inflammation with negative bacterial cx (CSF & blood)  
  
### Etiologies (Neurology 2006;66:75)  
  
- Viral: enteroviruses are most common cause (summer/fall; rash, GI, URI sx), HIV, HSV, VZV, mumps (parotitis), lymphocytic choriomeningitis virus (rodent exposure), encephalitis viruses, adenovirus, polio, CMV, EBV, WNV  
- Focal bacterial infection: brain/epidural/subdural abscess, CNS septic thrombophlebitis  
- Partially treated bacterial meningitis  
- Other infectious: TB, fungal (cryptococcus, coccidiodes), Lyme, syphilis, leptospirosis  
- Neoplasm: intracranial tumors (or cysts), lymphomatous or carcinomatous meningitis  
- Drug-induced meningitis: NSAIDs, IVIG, antibiotics (TMP-SMX, PCN), anti-epileptics  
- Systemic autoimmune illness: SLE, sarcoidosis, Behçet's, Sjögren's syndrome, RA  
- Mollaret's: recurrent lymphocytic meningitis, spontaneously resolving (often HSV-2)  
  
### Diagnosis  
  
- Obtain LP for CSF analysis: lymphocytic pleocytosis common in viral etiologies (see Typical CSF Findings in Meningitis table above)  
- Consider CSF cytology and MRI brain/spine to evaluate for malignancy  
- Consider serum autoimmune and serum viral testing in appropriate settings if CSF is unrevealing and there is no improvement with empiric treatment  
  
### Empiric treatment  
  
- Suspected bacterial meningitis: see empiric treatment of bacterial meningitis above  
- Suspected viral meningitis: if concern for HSV meningoencephalitis → IV acyclovir  
- Unclear etiology: consider initiation of empiric bacterial meningitis treatment while observing and awaiting CSF studies  
  
## ENCEPHALITIS (NEJM 2018;379:557)  
  
### Definition  
  
- Inflammation of brain parenchyma characterized by impaired cerebral function (AMS, neurologic deficits) often due to primary viral infection or post-viral inflammation  
  
### Etiologies (specific etiology found in <20% of cases; Neurology 2006;66:75; CID 2008;47:303)  
  
- HSV-1 all ages/seasons. If sxs recur after Rx, consider viral relapse vs. autoimmune encephalitis b/c high rates of autoimmune disease wks later (Lancet Neurol 2018;17:760)  
- VZV 1° or reactivation; ± vesicular rash; all ages (favors elderly), all seasons  
- Arboviruses: evaluate for exposure to vector/geography. Mosquitoes: West Nile, Eastern/Western equine, St. Louis, La Crosse; Ixodes tick: Powassan.  
- Enteroviruses (coxsackie, echo): preceding URI/ GI sx; peaks in late summer/early fall  
- Other infectious: CMV, EBV, HIV, JC, measles, mumps, rabies, adeno, influenza, Lyme  
- Non-infectious: autoimmune/paraneoplastic (anti-NMDAR, anti-Hu, anti-Ma2, anti-CRMP5, anti-mGluR5), post-infxn demyelination (eg, ADEM)  
  
### Clinical manifestations  
  
- Fever + ΔMS (subtle to severe), seizure, focal neuro deficit, HA in meningoencephalitis  
  
### Diagnostic studies (CID 2013;57:1114)  
  
- CSF analysis: lymphocytic pleocytosis; PCR for HSV (95% Se & Sp), VZV; consider other PCR based on risk factors (CMV/EBV, HIV, JC, adeno/enterovirus, WNV)  
- Consider testing for autoimmune etiologies and serologic viral testing in appropriate settings if CSF is unrevealing and there is no improvement with empiric HSV/VZV Rx  
- MRI (CT if unavailable); HSV temporal lobe; W. Nile & Powassan thalamic hyperintensity  
- EEG to r/o seizure; findings in encephalitis are nonspecific (temporal lobe focus in HSV)  
  
### Treatment  
  
- HSV/VZV: IV acyclovir 10 mg/kg IV q8h; consider empiric treatment given frequency  
  
## BELL'S PALSY  
  
### Definition & clinical manifestations  
  
- Acute idiopathic unilat. facial nerve palsy (CN VII), often presumed HSV reactivation  
- P/w unilateral facial muscle weakness, hyperacusis, ↓ taste, lacrimation, & salivation  
- Risk factors: pregnancy (preeclampsia), obesity, HTN, diabetes, preceding URI  
  
### Diagnosis (Otol Head Neck Surg 2013;149:656)  
  
- Labs, imaging, EMG not needed in routine cases  
- Ddx: Bilateral: Lyme, GBS, sarcoid. Additional neuro sx: stroke, tumor. Rash: herpes zoster. Other: otitis media, HIV, Sjögren.  
  
### Treatment and Prognosis (CMAJ 2014;186:917)  
  
- 70% recover spontaneously w/in 6 mos, >80% recover with glucocorticoid treatment  
- Oral corticosteroids started w/in 72 hrs of sx onset improve odds of recovery; dose varies based on severity (House-Brackmann grading). No conclusive data on antivirals.  
- If eyelid closure is compromised, eye protection is crucial to prevent trauma  
  
## HERPES ZOSTER (SHINGLES)  
  
### Definition & etiology  
  
- Painful vesicular rash in a peripheral nerve distribution due to reactivation of VZV  
- Spread by contact with active lesion (prior to crusting) in uncomplicated zoster or via airborne transmission in disseminated zoster  
  
### Clinical manifestations & complications  
  
- Uncomplicated: pain in a dermatomal distribution → dermatomal eruption of erythematous papules → vesicles → crusted plaques in varying stages of evolution  
- Disseminated: vesicles across multiple dermatomes, visceral organ involvement (pneumonia, hepatitis, CNS) seen in immunosupp. (eg, transplant, malignancy)  
- Zoster opthalmicus: ocular involvement (V1 of CN V) requires urgent ophtho eval  
- Post-herpetic neuralgia: neuropathic pain lasting >90 d after dx  
  
### Diagnosis  
  
- Clinical diagnosis if uncomplicated  
- Confirm with PCR (most sensitive), DFA, and viral culture (allows for resistance testing) of vesicular fluid (scrape from unroofed vesicle)  
  
### Treatment & prevention  
  
- Uncomplicated: acyclovir, valacyclovir, or famciclovir x 7 d; initiate w/in 72 h of onset for greatest benefit; consider after 72 h if new lesions present; minimal benefit after crusting  
- Superimposed bacterial cellulitis is common; if suspected, treat with appropriate antibiotics  
- Disseminated/immunosupp.: IV acyclovir, eval for visceral spread, droplet precautions  
- Prevention: Shingrix (2 doses) for all Pts >50; consider in younger if immunosupp.  
  
## 考古題  
### 專師  
  
  
### 內科醫師  
  
